Drug Type Small molecule drug |
Synonyms CDDP TI, IntraDose-CDDP, MPI-5010 |
Action agonists, inhibitors |
Mechanism ADRA1 agonists(Adrenergic receptor alpha-1 agonists), DNA inhibitors(DNA inhibitors), β-adrenoceptors agonists(Beta adrenergic receptors agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaCl2H6N2Pt |
InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N |
CAS Registry15663-27-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | United States | 01 May 1995 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Canada | 01 May 1995 | |
Refractory Head and Neck Carcinoma | Phase 3 | United States | 01 May 1995 | |
Refractory Head and Neck Carcinoma | Phase 3 | Canada | 01 May 1995 | |
Breast Cancer | Phase 3 | United States | - | |
Breast Cancer | Phase 3 | Europe | - | |
Breast Cancer | Phase 3 | - | - | |
Esophageal Carcinoma | Phase 3 | United States | - | |
Esophageal Carcinoma | Phase 3 | European Union | - | - |
Esophageal Carcinoma | Phase 3 | - | - |